New Wave
Mental Health
Projected global market for mental health / neurological disorders by 2025:
$128.9B
Scientific evidence is revealing a better path.
New research is emerging to reinforce the idea that psychedelic compounds have the potential to produce more effective mental health treatment options than the pharmaceutical products currently in use.
Leading global institutions have indicated that psilocybin-assisted therapy could be a revolutionary treatment for:
- Tobacco and alcohol addiction
- Depression and anxiety in cancer patients
- General depression
The FDA has granted “breakthrough therapy” status to further the study of psilocybin and ketamine remedies.
IP Development
The company is building a scientific advisory board to expedite the development of New Wave’s psychedelic medical research portfolio.
Just how pervasive are mental health issues?
Take a look at the US alone:
- 40 Million Adults affected by anxiety.
- 10 Million Adults us stimulant prescription medicines for ADHD.
- 20 Million Americans have substance abuse disorders.
- 17 Million Adults suffer with major depression
- Opioid addiction is arguably the biggest mental health problem facing North America 500 Billion Annual cost
- Addicts, their families and their communities are desperate for a solution that works 42 Billion projected spend on Rehab.
Invest with us
Download our investor presentation to learn more about New Wave Holding and the opportunities ahead.